AI Article Synopsis
- Tacrolimus is used as an immunosuppressive treatment for ulcerative colitis (UC), and its effects can vary based on genetic differences in patients' CYP3A5 gene.
- A study with 29 UC patients showed that those with the CYP3A5 expressers had significantly lower tacrolimus concentration-to-dose (C/D) ratios and experienced more adverse events like nephrotoxicity compared to non-expressers.
- Understanding the relationship between CYP3A5 polymorphisms and side effects can help manage treatment better, especially regarding the risk of nephrotoxicity in expressers.
Article Abstract
Background: Tacrolimus is an immunosuppressive agent, used in the remission induction therapy of ulcerative colitis (UC).
Aims: We investigated the correlation between CYP3A5 genetic polymorphisms and the adverse events in patients with UC. The pharmacokinetics of tacrolimus after oral administration were also analyzed.
Methods: We enrolled 29 hospitalized patients with UC received oral tacrolimus. Genotyping for CYP3A5 A6986G (rs776746) was performed using Custom TaqMan SNP genotyping assays. Adverse events, concentration and dose (C/D) ratios and clinical outcomes were investigated.
Results: CYP3A5 expressers and non-expressers were 16 and 13, respectively. C/D ratios of CYP3A5 expressers were significantly lower compared to non-expressers. The response rate in CYP3A5 non-expressers was relatively higher in the early phase of treatment compared to expressers, but not statistically significant. The incidence of overall adverse events was significantly higher in CYP3A5 expressers than in non-expressers (P=0.034, chi-squared test). In particular, the incidence of nephrotoxicity was significantly higher in CYP3A5 expressers compared to non-expressers (P=0.027, chi-squared test). All of the nephrotoxicity were reversible and resolved by discontinuation or dose reduction of tacrolimus.
Conclusion: The adverse events especially nephrotoxicity were frequently observed in CYP3A5 expressers. CYP3A5 expressers should be paid attention to the onset of nephrotoxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dld.2016.09.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients.
Diagnostics (Basel)
October 2024
Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Article Synopsis
- The study aimed to determine if early genotype-based dosage adjustment of tacrolimus based on CYP3A5-expression status could improve outcomes in renal transplant recipients.
- Among 160 patients studied, 21% were identified as CYP3A5 expressers, requiring higher tacrolimus doses, but overall, tacrolimus levels and transplant outcomes (like rejection and DSA formation) were similar in both expressers and nonexpressers.
- Early detection and adjustment of tacrolimus dosages did not lead to higher rates of nephrotoxicity, suggesting potential benefits for patient management in renal transplants.
Revisiting the nature and pharmacodynamics of tacrolimus metabolites.
Pharmacol Res
November 2024
Université de Limoges, Inserm, UMR1248, Pharmacology & Transplantation P&T, Limoges, France; Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France. Electronic address:
The toxicity of tacrolimus metabolites and their potential pharmacodynamic (PD) interactions with tacrolimus might respectively explain the surprising combination of higher toxicity and lower efficacy of tacrolimus despite normal blood concentrations, described in extensive metabolizers. To evaluate such interactions, we produced tacrolimus metabolites in vitro and characterized them by high resolution mass spectrometry (HRMS, for all) and nuclear magnetic resonance (NMR, for the most abundant, M-I). We quantified tacrolimus metabolites and checked their structure in patient whole blood and peripheral blood mononuclear cells (PBMC).
View Article and Find Full Text PDFDrug-drug interaction between diltiazem and tacrolimus in relation to CYP3A5 genotype status in Chinese pediatric patients with nephrotic range proteinuria: a retrospective study.
Front Pharmacol
September 2024
Department of Pharmacy, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background: Tacrolimus is widely used to treat pediatric nephrotic range proteinuria (NRP). Diltiazem, a CYP3A4/5 inhibitor, is often administered with tacrolimus, affecting its pharmacokinetic profile. The impact of this combination on tacrolimus exposure, particularly in CYP3A5*3 genetic polymorphism, remains unclear in pediatric NRP patients.
View Article and Find Full Text PDFInteraction between tacrolimus and calcium channel blockers based on CYP3A5 genotype in Chinese renal transplant recipients.
Front Pharmacol
August 2024
Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, Shandong, China.
Objective: To investigate the effect of calcium channel blockers (CCBs) on tacrolimus blood concentrations in renal transplant recipients with different genotypes.
Methods: This retrospective cohort study included renal transplant recipients receiving tacrolimus-based immunosuppressive therapy with or without CCBs in combination. Patients were divided into combination and control groups based on whether or not they were combined with CCBs, and then further analyzed according to the type of CCBs (nifedipine/amlodipine/felodipine).
Factors and interventions affecting tacrolimus intrapatient variability: A systematic review and meta-analysis.
Transplant Rev (Orlando)
December 2024
Department of Pharmacy, Peking University Third Hospital, Beijing, China. Electronic address:
Backgrounds: Tacrolimus is a cornerstone of posttransplantation immunosuppressive regimens. Despite routine monitoring, the efficacy of its trough concentrations in reflecting drug concentration fluctuations is limited. Intrapatient variability (IPV) emerges as a novel monitoring marker for predicting clinical outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!